LOS ANGELES--(BUSINESS WIRE)--
Goldberg Law PC announces that it is investigating Intra-Cellular Therapies, Inc. (“Intra-Cellular Therapies” or the “Company”) (Nasdaq: ITCI) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Intra-Cellular Therapies shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].
The investigation concerns whether Intra-Cellular Therapies and certain of its officers and/or directors violated federal securities laws. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” On May 1, 2017, Intra-Cellular Therapies disclosed that the U.S. Food & Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients. When this news was announced, Intra-Cellular Therapies’ stock price dropped sharply.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [email protected].
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170502006357/en/
